All In Biotech

Free tool

FAERS Monitor: Vivimusta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212209 or its brand name (Vivimusta, Bendamustine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

7,958

Serious

7,618

96% of reports

Hospitalization

3,240

Death reported

1,556

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use995
  • pyrexia555
  • disease progression510
  • covid-19406
  • product use in unapproved indication401
  • drug ineffective392
  • febrile neutropenia366
  • malignant neoplasm progression362
  • neutrophil count decreased354
  • neutropenia345
  • platelet count decreased342
  • pneumonia342
  • anaemia321
  • myelosuppression276
  • prescribed underdose271

Reports by year received

View as table
YearReports
20081
20093
20102
201115
2012129
201346
2014267
2015423
2016435
2017400
2018594
2019583
2020607
2021731
20221,445
20231,011
2024735
2025299
2026232

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,201 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
prescribed underdoseSignal27136.432.39,173
neutrophil count decreasedSignal35423.120.97,429
myelosuppressionSignal27620.418.25,043
febrile neutropeniaSignal36614.713.34,633
disease progressionSignal51011.410.54,853
malignant neoplasm progressionSignal3629.48.52,703
platelet count decreasedSignal3428.57.72,262
neutropeniaSignal3456.76.11,681
covid-19Signal4066.15.61,748
anaemiaSignal3214.54.0863
product use in unapproved indicationSignal4014.33.91,016
pyrexiaSignal5554.23.91,394
off label useSignal9953.02.81,386
pneumoniaSignal3422.82.5398
drug ineffective3920.80.724

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.